Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience

Yilmaz U., Yilmaz U., Yasar Z., Kirakli E. K., Ulger S., Ozdogan Y., ...More

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.12, no.1, pp.334-339, 2016 (SCI-Expanded) identifier identifier identifier


Aim: Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey.